Order Article Reprints

Kuitunen HK, Rönkä ALK, Sonkajärvi EM, Isokangas J-M, Pyörälä M, Palosaari KAA, Jokimäki AS, Partanen AE, Littow HJ, Vakkala MA, et al. Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study. Cancers. 2023; 15(4):1341. https://doi.org/10.3390/cancers15041341

Kuitunen, Hanne K., Aino L. K. Rönkä, Eila M. Sonkajärvi, Juha-Matti Isokangas, Marja Pyörälä, Kari A. A. Palosaari, Anna S. Jokimäki, Anu E. Partanen, Harri J. Littow, Merja A. Vakkala, and et al. 2023. "Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study" Cancers 15, no. 4: 1341. https://doi.org/10.3390/cancers15041341

Kuitunen, H. K., Rönkä, A. L. K., Sonkajärvi, E. M., Isokangas, J.-M., Pyörälä, M., Palosaari, K. A. A., Jokimäki, A. S., Partanen, A. E., Littow, H. J., Vakkala, M. A., Jantunen, E. J., Huttunen, M. E., Marin, K. J., Aromaa-Häyhä, A. M. K., Auvinen, P. K., Selander, T., Puhakka, I. K., & Kuittinen, O. M. (2023). Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study. Cancers, 15(4), 1341. https://doi.org/10.3390/cancers15041341